Entropin, Inc. Announces Conference Call to Provide Clinical Update And Year-End 2000 Financial Results

Apr 05, 2001, 01:00 ET from Entropin, Inc.

    INDIO, Calif., April 5 /PRNewswire/ -- Entropin, Inc. (Nasdaq: ETOP), a
 pharmaceutical company developing Esterom(R) solution, a topical therapeutic
 for acute painful shoulder and lower back sprain, today announced that it will
 provide an update on Esterom(R) clinical progress and discuss the company's
 year-end 2000 financial results on Monday, April 16, 2001.
     Entropin management will hold a conference call Monday, April 16, at
 1 p.m. PDT (4 p.m. EDT) to discuss year-end financial results and provide a
 clinical progress update including the: analysis of Phase III trial results,
 outcome of the company's recent meeting with the Food and Drug Administration,
 and protocol for the upcoming trial designed with guidance from Entropin's
 expert advisory panel.
     To listen to the conference call live, please call 1-888-423-3280 (or
 1-612-288-0337 from outside the U.S.).  A digital replay of the conference
 call will be available from 5:00 pm PDT on Monday, April 16, until 11:59 pm on
 Monday, April 30, 2001.  The call-in number for the replay is 1-800-475-6701
 (or 1-320-365-3844 from outside the U.S.).  The access number for the taped
 replay is 581117.
     The conference call will also be broadcast via live webcast.  To access
 this broadcast, go to www.vcall.com.  Enter ETOP in the ticker box and click
 on GO.  Please go to the website at least fifteen minutes prior to the call to
 register and download and install any necessary audio software.  An archived
 copy of the webcast will be available for 60 days from the date of the call.
 
     Entropin, Inc. is a pharmaceutical research and development company
 focused on the development of a novel topical therapeutic called Esterom(R)
 solution as a treatment for impaired range of motion associated with acute
 painful shoulder and acute lower back sprain.  The company recently completed
 a Phase III trial of Esterom(R) solution in patients with impaired shoulder
 function, and plans to initiate its next study in the third quarter of 2001.
 
     Safe Harbor Statement Under the Private Securities Litigation Reform Act
 of 1995: This release includes forward-looking statements that reflect
 Entropin's current views with respect to future events and financial
 performance.  The words "believe," "expect," "anticipate" and similar
 expressions identify forward-looking statements.  Investors should not rely on
 forward-looking statements because they are subject to a variety of risks,
 uncertainties, and other factors that could cause actual results to differ
 materially from those expressed in any such forward-looking statements.  These
 factors include, but are not limited to: (1) the ability to successfully
 complete development and commercialization of products, including the cost,
 scope and results of preclinical and clinical testing; (2) the ability to
 successfully complete product research and further development, including
 animal, pre-clinical and clinical studies; (3) the time, cost and uncertainty
 of obtaining regulatory approvals; (4) the ability to obtain substantial
 additional funding; (5) the ability to develop and commercialize products
 before competitors; and (6) other factors detailed from time to time in
 filings with the Securities and Exchange Commission.
 
 

SOURCE Entropin, Inc.
    INDIO, Calif., April 5 /PRNewswire/ -- Entropin, Inc. (Nasdaq: ETOP), a
 pharmaceutical company developing Esterom(R) solution, a topical therapeutic
 for acute painful shoulder and lower back sprain, today announced that it will
 provide an update on Esterom(R) clinical progress and discuss the company's
 year-end 2000 financial results on Monday, April 16, 2001.
     Entropin management will hold a conference call Monday, April 16, at
 1 p.m. PDT (4 p.m. EDT) to discuss year-end financial results and provide a
 clinical progress update including the: analysis of Phase III trial results,
 outcome of the company's recent meeting with the Food and Drug Administration,
 and protocol for the upcoming trial designed with guidance from Entropin's
 expert advisory panel.
     To listen to the conference call live, please call 1-888-423-3280 (or
 1-612-288-0337 from outside the U.S.).  A digital replay of the conference
 call will be available from 5:00 pm PDT on Monday, April 16, until 11:59 pm on
 Monday, April 30, 2001.  The call-in number for the replay is 1-800-475-6701
 (or 1-320-365-3844 from outside the U.S.).  The access number for the taped
 replay is 581117.
     The conference call will also be broadcast via live webcast.  To access
 this broadcast, go to www.vcall.com.  Enter ETOP in the ticker box and click
 on GO.  Please go to the website at least fifteen minutes prior to the call to
 register and download and install any necessary audio software.  An archived
 copy of the webcast will be available for 60 days from the date of the call.
 
     Entropin, Inc. is a pharmaceutical research and development company
 focused on the development of a novel topical therapeutic called Esterom(R)
 solution as a treatment for impaired range of motion associated with acute
 painful shoulder and acute lower back sprain.  The company recently completed
 a Phase III trial of Esterom(R) solution in patients with impaired shoulder
 function, and plans to initiate its next study in the third quarter of 2001.
 
     Safe Harbor Statement Under the Private Securities Litigation Reform Act
 of 1995: This release includes forward-looking statements that reflect
 Entropin's current views with respect to future events and financial
 performance.  The words "believe," "expect," "anticipate" and similar
 expressions identify forward-looking statements.  Investors should not rely on
 forward-looking statements because they are subject to a variety of risks,
 uncertainties, and other factors that could cause actual results to differ
 materially from those expressed in any such forward-looking statements.  These
 factors include, but are not limited to: (1) the ability to successfully
 complete development and commercialization of products, including the cost,
 scope and results of preclinical and clinical testing; (2) the ability to
 successfully complete product research and further development, including
 animal, pre-clinical and clinical studies; (3) the time, cost and uncertainty
 of obtaining regulatory approvals; (4) the ability to obtain substantial
 additional funding; (5) the ability to develop and commercialize products
 before competitors; and (6) other factors detailed from time to time in
 filings with the Securities and Exchange Commission.
 
 SOURCE  Entropin, Inc.